SCHEMBL31425931

SCHEMBL31425931

COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)cc2c1cc(C)c(=O)n2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ PDE4A P27815 2/20 0.42
▸ PDE4C Q08493 2/20 0.42
▸ PDE4D Q08499 2/20 0.42
▸ STS P08842 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ PIK3CA P42336 2/20 0.41
▸ PRKDC P78527 2/20 0.41
▸ MTOR P42345 1/20 0.41
▸ NAMPT P43490 1/20 0.40
▸ NPBWR1 P48145 1/20 0.40
▸ MCHR1 Q99705 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ QDPR P09417 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31542308 0.88 KDM4E (0.47) PDE4BKDM4EMAPTTHRBKMT2A
SCHEMBL31542325 0.86 KDM4E (0.41) PDE4BKDM4EMAPTTHRBSTS
SCHEMBL31425891 0.83 ADAM17 (0.44) PDE4BKDM4EQDPR
SCHEMBL31425919 0.83 MAPK14 (0.38) MEN1KMT2AQDPRTP53
SCHEMBL31496296 0.81 ALDH1A1 (0.42) KDM4EMAPTMEN1KMT2AGPR119
SCHEMBL31426008 0.80 LMNA (0.40) KDM4EMEN1KMT2ANAMPTALDH1A1
SCHEMBL19703151 0.78 ADAM17 (0.54) PDE4BKDM4EMAPTTHRBMEN1
SCHEMBL31426032 0.78 BRPF1 (0.38) PDE4BKDM4EALDH1A1QDPRHPGD
SCHEMBL19703066 0.78 PDE4B (0.56) PDE4BKDM4EMAPTTHRBMEN1
SCHEMBL21403986 0.78 PDE4B (0.56) PDE4BKDM4EMAPTTHRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-04-10 — — US disclosed
WO-2025062330-A1 HETEROCYCLIC COMPOUNDS AS CBP SELECTIVE DEGRADERS AURIGENE ONCOLOGY LIMITED (IN) 2025-03-27 — — WO disclosed
WO-2025049994-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2025-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF EP300, CREBBP, HDAC1 PDE4B 3455/4885KDM4E 200/4885MAPT 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback